Pfizer and BridgeBio have secured a significant patent victory, which may influence their future operations and market strategies.
In related news, the FDA is implementing changes to its clinical trial data review process, potentially affecting how new treatments are evaluated.
Additionally, Rocket Pharmaceuticals has sold its priority review voucher, a move that could have implications for its pipeline and funding.